Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today the pricing of its previously announced underwritten public offering of 8,333,334 of its ordinary shares at a price to the public of $12.00 per ordinary share. Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses. All of the ordinary shares in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 1,250,000 of its ordinary shares on the same terms and conditions. The offering is expected to close on or about September 25, 2020, subject to customary closing conditions.

Jefferies, SVB Leerink and Mizuho Securities are acting as joint book-running managers for the offering. Truist Securities and H.C. Wainwright & Co. are acting as co-managers for the offering.